Figures & data
Table 1 Time to peak plasma concentration of conjugated taxane with various CT-2103 doses
Table 2 Baseline patient characteristics
Figure 1 Prothrombin time (PT) and activated thromboplastin time (aPTT) values versus CT-2103 concentration.
Figure 2 Activated thromboplastin time (aPTT) values over time following CT-2103 administration per patient. Patient identification numbers are shown in the margin.
Figure 3 Dose-response curve of heparin/antithrombin III complex inhibition of both thrombin and factor Xa activity.
Table 3 CT-2103 inhibition of α-thrombin activity in heparin assay
Table 4 CT-2103 inhibition of factor Xa activity in heparin assay
Table 5 Factor IIa and Xa inhibition is independent of antithrombin III
Table 6 Raw data for factors IXa, XIa, and XII